HER2阳性乳腺癌靶向治疗的进展与未来方向：对未来的启示
Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.
作者信息
Subbiah Ishwaria M, Gonzalez-Angulo Ana Maria
机构信息
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.
出版信息
Curr Treat Options Oncol. 2014 Mar;15(1):41-54. doi: 10.1007/s11864-013-0262-4.
Abstract
The natural history of HER2-positive breast cancer significantly changed in the past 15 years. Form being the most aggressive type of breast cancer, it became treatable with important cure rates. However, with new and successful drugs, resistance emerges. Progress in research and drug development continues to make available effective anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the data that support the indications of each compound and to continue clinical trial participation.
摘要
在过去15年中，HER2阳性乳腺癌的自然病程发生了显著变化。它曾是最具侵袭性的乳腺癌类型，如今已可通过重要的治愈率进行治疗。然而，随着新的成功药物的出现，耐药性也随之产生。研究和药物开发的进展继续提供有效的抗HER2疗法。我们如今面临的挑战是通过审视支持每种化合物适应证的数据来正确使用这些工具，并继续参与临床试验。
相似文献
1
Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.HER2阳性乳腺癌靶向治疗的进展与未来方向：对未来的启示
Curr Treat Options Oncol. 2014 Mar;15(1):41-54. doi: 10.1007/s11864-013-0262-4.
2
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.曲妥珠单抗和拉帕替尼耐药的 HER2 阳性乳腺癌细胞丧失对 HER2 的依赖，并对多靶点激酶抑制剂索拉非尼敏感。
Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.
3
[Her2 a paradigm for targeted therapy].[人表皮生长因子受体2：靶向治疗的范例]
Bull Cancer. 2011 Oct;98(9):1011-7. doi: 10.1684/bdc.2011.1379.
4
HER2-directed therapy: current treatment options for HER2-positive breast cancer.HER2靶向治疗：HER2阳性乳腺癌的当前治疗选择
Breast Cancer. 2015 Mar;22(2):101-16. doi: 10.1007/s12282-015-0587-x. Epub 2015 Jan 30.
5
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.PI3Kα/δ显性抑制剂BAY 80 - 6946在对HER2靶向治疗药物曲妥珠单抗和拉帕替尼产生获得性耐药的HER2阳性乳腺癌模型中的临床前评估。
Breast Cancer Res Treat. 2015 Jan;149(2):373-83. doi: 10.1007/s10549-014-3239-5. Epub 2014 Dec 21.
6
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?PI3激酶激活与曲妥珠单抗治疗反应：对赫赛汀耐药有何新情况？
Cancer Cell. 2007 Oct;12(4):297-9. doi: 10.1016/j.ccr.2007.10.004.
7
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.疾病机制：了解人类乳腺癌对HER2靶向治疗的耐药性
Nat Clin Pract Oncol. 2006 May;3(5):269-80. doi: 10.1038/ncponc0509.
8
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.乳腺癌中 HER2-PI3K 信号的最佳靶向治疗：机制见解与临床意义。
Cancer Res. 2013 Jul 1;73(13):3817-20. doi: 10.1158/0008-5472.CAN-13-0687. Epub 2013 Jun 21.
9
The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.表皮生长因子受体1和表皮生长因子受体2通路抑制在乳腺癌治疗中的未来：靶向多种受体
Oncologist. 2004;9 Suppl 3:1-3. doi: 10.1634/theoncologist.9-suppl_3-1.
10
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.一种功能遗传学方法确定PI3K通路是乳腺癌中曲妥珠单抗耐药的主要决定因素。
Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030.
引用本文的文献
1
The HER2 target for designing novel multi-peptide vaccine against breast cancer using immunoinformatics and molecular dynamic simulation.利用免疫信息学和分子动力学模拟设计新型抗乳腺癌多肽疫苗的HER2靶点。
Biochem Biophys Rep. 2025 Jul 4;43:102135. doi: 10.1016/j.bbrep.2025.102135. eCollection 2025 Sep.
2
Comprehensive advances in HER2-positive and HER2-negative breast cancer: unveiling molecular mechanisms and exploring cutting-edge targeted therapies for enhanced patient outcomes.HER2阳性和HER2阴性乳腺癌的全面进展：揭示分子机制并探索前沿靶向治疗以改善患者预后。
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 29. doi: 10.1007/s00210-025-04204-w.
3
Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing.微免疫反应芯片（MIRO）用于模拟肿瘤-基质界面以进行免疫治疗测试。
Nat Commun. 2025 Feb 3;16(1):1279. doi: 10.1038/s41467-025-56275-1.
4
Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.针对不同的癌相关成纤维细胞的靶向免疫疗法克服了难治性 HER2+ 乳腺癌肿瘤的治疗抵抗。
Nat Commun. 2022 Sep 9;13(1):5310. doi: 10.1038/s41467-022-32782-3.
5
Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.在 HER2+ 乳腺癌模型中解除 MYC 的调控可模拟人类肿瘤间异质性。
J Clin Invest. 2020 Jan 2;130(1):231-246. doi: 10.1172/JCI126390.
6
Cytotoxic Activity and Memory T Cell Subset Distribution of -Stimulated CD8 T Cells Specific for HER2/neu Epitopes.针对 HER2/neu 表位的 - 刺激 CD8 T 细胞的细胞毒性活性和记忆 T 细胞亚群分布。
Front Immunol. 2019 May 9;10:1017. doi: 10.3389/fimmu.2019.01017. eCollection 2019.
7
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.HER2阳性乳腺癌的免疫治疗：最新进展与联合治疗方法
Breast Cancer (Dove Med Press). 2019 Jan 17;11:53-69. doi: 10.2147/BCTT.S175360. eCollection 2019.
8
Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.使用转染了编码HER2/neu肿瘤抗原表位的DNA构建体的树突状细胞生成抗原特异性细胞毒性T细胞群体。
BMC Immunol. 2017 Jun 20;18(1):31. doi: 10.1186/s12865-017-0219-7.
9
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.在BOLERO-1研究中，依维莫司联合曲妥珠单抗和紫杉醇用于亚洲HER2阳性晚期乳腺癌患者的疗效和安全性。
Breast Cancer Res. 2017 Apr 11;19(1):47. doi: 10.1186/s13058-017-0839-0.
10
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.恢复乳腺癌中丧失的抗HER-2 Th1免疫：Th1细胞因子在治疗和预防中的关键作用
Front Pharmacol. 2016 Oct 6;7:356. doi: 10.3389/fphar.2016.00356. eCollection 2016.
本文引用的文献
1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.帕妥珠单抗、曲妥珠单抗和多西他赛联合用于人表皮生长因子受体 2 阳性转移性乳腺癌（CLEOPATRA 研究）：一项随机、双盲、安慰剂对照、3 期研究的总生存结果。
Lancet Oncol. 2013 May;14(6):461-71. doi: 10.1016/S1470-2045(13)70130-X. Epub 2013 Apr 18.
2
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.曲妥珠单抗-美坦新偶联物对比曲妥珠单抗联合多西他赛用于人表皮生长因子受体 2 阳性转移性乳腺癌的 II 期随机研究。
J Clin Oncol. 2013 Mar 20;31(9):1157-63. doi: 10.1200/JCO.2012.44.9694. Epub 2013 Feb 4.
3
Trastuzumab emtansine for HER2-positive advanced breast cancer.曲妥珠单抗-美坦新偶联物用于治疗人表皮生长因子受体 2 阳性的晚期乳腺癌。
N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1.
4
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
5
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.曲妥珠单抗-美坦新偶联物治疗既往接受曲妥珠单抗、拉帕替尼、蒽环类药物、紫杉烷和卡培他滨治疗的人表皮生长因子受体 2 阳性转移性乳腺癌患者的 II 期研究。
J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29.
6
Trastuzumab containing regimens for early breast cancer.含曲妥珠单抗的早期乳腺癌治疗方案。
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD006243. doi: 10.1002/14651858.CD006243.pub2.
7
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
8
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.帕妥珠单抗联合曲妥珠单抗加多西他赛治疗转移性乳腺癌。
N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
9
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.曲妥珠单抗联合辅助化疗治疗可手术的人表皮生长因子受体 2 阳性乳腺癌的 4 年随访：NCCTG N9831 和 NSABP B-31 数据的联合分析。
J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.
10
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.曲妥珠单抗联合依维莫司（RAD001）治疗曲妥珠单抗治疗后进展的人表皮生长因子受体 2 过表达转移性乳腺癌患者的 I/II 期研究。
J Clin Oncol. 2011 Aug 10;29(23):3126-32. doi: 10.1200/JCO.2010.32.2321. Epub 2011 Jul 5.
Zotero 插件